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Abstract
Galectins have emerged as potent immunoregulatory agents that control chronic inflamma-
tion through distinct mechanisms. Here, we report that treatment with Galectin-8 (Gal-8), a
tandem-repeat member of the galectin family, reduces retinal pathology and prevents pho-
toreceptor cell damage in a murine model of experimental autoimmune uveitis. Gal-8 treat-
ment increased the number of regulatory T cells (Treg) in both the draining lymph node
(dLN) and the inflamed retina. Moreover, a greater percentage of Treg cells in the dLN and
retina of Gal-8 treated animals expressed the inhibitory coreceptor cytotoxic T lymphocyte
antigen (CTLA)-4, the immunosuppressive cytokine IL-10, and the tissue-homing integrin
CD103. Treg cells in the retina of Gal-8-treated mice were primarily inducible Treg cells that
lack the expression of neuropilin-1. In addition, Gal-8 treatment blunted production of
inflammatory cytokines by retinal T helper type (TH) 1 and TH17 cells. The effect of Gal-8 on
T cell differentiation and/or function was specific for tissues undergoing an active immune
response, as Gal-8 treatment had no effect on T cell populations in the spleen. Given the
need for rational therapies for managing human uveitis, Gal-8 emerges as an attractive ther-
apeutic candidate not only for treating retinal autoimmune diseases, but also for other TH1-
and TH17-mediated inflammatory disorders.
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Introduction
Autoimmune uveitis is a spectrum of inflammatory diseases that can affect any part of the
eye, and collectively results in 10–20% of all cases of blindness in the United States [1].
Patients with autoimmune uveitis display strong T helper type (TH)1 and TH17 responses [2],
[3], and are relatively deficient in regulatory T cells (Treg cells) [4]. Surface expression of the
inhibitory coreceptor cytotoxic T lymphocyte antigen-4 (CTLA-4) on Treg cells is higher in
uveitis patients who respond well to treatment than on Treg cells from patients with active
disease [4]. The immunopathology of uveitis has been extensively studied using rodent models
of experimental autoimmune uveitis (EAU), which faithfully recapitulate aspects of human
uveitis pathology, including immune cell pathophysiology. These studies have shown that
depletion of Treg cells during active disease significantly increases EAU severity and favors
the presence of TH1 and TH17 cells in draining lymph nodes (dLN) [5]. Conversely, Treg cell
infusion before the onset of EAU ameliorates pathology [6]. Previous work has shown that
skewing the T cell response towards TH2 and Treg and away from TH1 and TH17 suppresses
EAU [7].
Due to the key role of Treg cells in preventing autoimmunity, there is intense interest in
manipulating the signals responsible for generating and maintaining these cells. Although the
generation and regulation of Treg cells is a complex and incompletely understood process, it is
known that Treg cell development in the periphery depends on interleukin-2 (IL-2) and TGFβ
signaling [8]. Recent studies have provided evidence that members of the galectin family also
have the potential to modulate the generation and stability of Treg cells [7],[9–13]. Galectins
constitute a family of animal lectins characterized by their affinity for β-galactoside-containing
glycans. Galectins play an important role in many biological processes including, but not lim-
ited to, immune regulation, host-pathogen interactions, angiogenesis, and fibrosis [14–17]. In
recent years, the ability of galectins to regulate the immune system has attracted much interest
based on accumulating evidence implicating members of the galectin family as a novel class of
modulators of innate and adaptive immune functions, and their potential as therapeutic agents
for autoimmune disorders. Galectin-9 (Gal-9) has been shown to significantly reduce pathol-
ogy of experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclero-
sis [18], whereas Gal-1 prevents ocular pathology in EAU [7] as well as EAE [19]. Gal-3
inhibits Treg cell differentiation and function [20], whereas Gal-1 and -9 enhance the fre-
quency and immunosuppressive capacity of Treg cells [12],[21]. Gal-8 is a tandem-repeat type
member of the galectin family, with two structurally distinct carbohydrate recognition domains
(CRDs). The N-terminal CRD preferentially binds to α2,3-sialylated glycans, a unique specific-
ity among galectins [22]. Although the expression of Gal-8 is markedly increased in response
to inflammation (Chen, et al. in preparation), its role in the regulation of the immune system is
poorly understood, and nothing is known about the role of Gal-8 in autoimmune diseases such
as uveitis.
We demonstrate here that Gal-8 treatment reduces retinal pathology and photoreceptor
cell damage in the mouse model of EAU, and that reduction in retinal pathology is associated
with a concomitant increase in the anti-inflammatory Treg cell response in the dLN and ret-
ina, and a decrease in TH1 and TH17 cytokine production locally in the retina. We further
show that a higher percentage of Treg cells from Gal-8-treated mice express the inhibitory
coreceptor, CTLA-4, the immunosuppressive cytokine IL-10, and the tissue-homing integrin
CD103, as compared to Treg cells from vehicle-treated mice. Thus, the inhibitory effect of
Gal-8 on EAU appears to be a result of selectively modulating the immune response in the
eye.
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Materials and Methods
Ethics statement
All animal procedures were approved by the IACUC committees of Tufts University (#B2013-
159) and Harvard Medical School (#10-032A). Mice were anesthetized with avertin prior to
ocular imaging. Prior to euthanasia by cervical dislocation, mice were administered ketamine
and xylazine.
Mice
C57BL/6J (B6) mice were obtained from the Jackson Laboratory and maintained in animal
facilities approved by the Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC) at Tufts University (IACUC #B2013-159) and Harvard Medical School
(IACUC #10-032A). Unlike C57BL/6N mice, B6J mice do not have the Rd8mutation that
causes retinal pathology [23]. This was verified by genotyping. All animal study protocols con-
formed to the Association for Research in Vision and Ophthalmology resolution on the use of
Animals in Vision Research and the recommendations of the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
Reagents, Antigens (Ags), and Monoclonal Antibodies (mAbs)
CFA was purchased from Sigma, and B. pertussis toxin was purchased from Invitrogen.
Human interphotoreceptor retinoid-binding protein (IRBP) peptide1–20
(GPTHLFQPSLVLDMAKVLLD) was purchased from Biomatik. The following antibodies
were purchased from eBioscience, as conjugated to FITC, PE, or allophycocyanin: IFNγ
XMG1.2), IL-17A (eBio17B7), Forkhead box P3 (Foxp3, FJK-16S), CTLA-4 (UC10-4B9), IL-
10 (JES5-16E3), neuropilin-1 (3DS304M), and isotype controls. The following antibodies were
purchased from BD, as conjugated to FITC, PE, or allophycocyanin: CD4 (RM4-5), CD103
(M290), IL-4 (11B11), and isotype controls.
Preparation of recombinant human glutathione S-transferase tagged
Gal-8
Recombinant human glutathione S-transferase (GST) tagged Gal-8 was produced and purified
as previously described [24]. Briefly, lysates of bacteria expressing GST-Gal-8 were chromato-
graphed on a β-lactose-conjugated Sepharose column, and bound to an affinity matrix (EY
Labs; 1 ml bed volume). GST-Gal-8 was eluted from the column with lactose. Fractions con-
taining the lectin were dialyzed against PBS containing 2% glycerol and 4 mM β-mercaptoetha-
nol and stored at −80°C.
EAU induction and treatment with Gal-8
EAU was induced in eight week old B6 female mice as previously described [25],[26]. Briefly,
B6 mice were immunized s.c. in the scruff, femur, and foot pad with a total of 200 μg of IRBP
peptide1–20 emulsified in complete Freund’s adjuvant (CFA, H37Ra, Difco Laboratories). Mice
were simultaneously injected i.p. with 100 μl (1.5 μg) of B. pertussis toxin. On days 2, 4, 6, 14,
16, 18, and 22 post immunization (p.i.), mice were injected i.p. with 50 μg Gal-8 diluted in
100 μl PBS or an equal volume of buffer control (vehicle). Gal-8 treatment began on day 2 to
ensure that the lectin was present during T cell activation [7], and we selected 50 μg per mouse
as has been previously used for other galectins [7].
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Imaging mouse fundus and grading system
Mice were anesthetized with an i.p. injection of avertin (Sigma) diluted in saline. Pupils were
dilated with one drop of a solution of 0.5% (w/v) tropicamide and 5% (w/v) phenylephrine
(MEEI pharmacy). Goniovisc (2.5%, HUB pharmaceuticals) was used as a corneal medium
during imaging. A Micron III Retinal Imaging Microscope and StreamPix software (Phoenix
Research Labs) were used to image the fundus. Scoring was as reported previously [7],[26].
Briefly, retinal infiltrates, optic disc changes, vascularity, and structural damage were scored on
a scale of 0–4. Infiltrates: 1 = 1–4 small lesions or 1 linear lesion, 2 = 5–10 small lesions or 2–3
linear lesions, 3 =>10 small lesions or>3 linear lesions, 4 = confluent linear lesions. Optic
disc: 1 = minimal inflammation, 2 = mild inflammation, 3 = moderate inflammation, 4 = severe
inflammation. Retinal vessels: 1 = engorged vessels, no cuffing, 2 = engorged vessels, 1–4 mild
cuffs, 3 =>4 mild cuffs or 1–3 moderate cuffs, 4 =>3 moderate cuffs,>1 severe cuff. Struc-
tural damage: 1 = lesions or atrophy on<1/4 of retina, 2 = lesions or atrophy on 1/4-3/4 of ret-
ina, 3 = pan retinal atrophy with multiple small scars or<3 linear scars, 4 = pan retinal
atrophy with>3 linear or confluent scars. Clinical score was calculated by averaging the score
for each of the four criteria.
Determination of photoreceptor pathology
Mice were anesthetized with avertin to prevent movement and pupils were dilated with tropi-
camide and phenylephrine as above. Mice were then placed on a custom, free-rotating platform
while focusing on the retina. Lesions were first identified by fundus imaging, then spectral
domain optical coherence tomography (OCT) images were acquired using a Micron III Retinal
Imaging Microscope with an OCT attachment (Phoenix Research Labs). Ten sequential images
were averaged to yield the presented composite images.
Histopathology
To confirm OCT and fundoscopy observations, eyes were enucleated 24 d p.i. and processed
for histopathology. Briefly, eyes were fixed in Davidson’s fixative (32% ethanol, 2.2% buffered
formalin, 11% glacial acetic acid) for 24 h, embedded in paraffin, and 5 μm sections were
stained with standard eosin and hematoxylin [27]. Presence or absence of disease was scored in
a blinded fashion by two independent observers examining 10 sections of each eye at different
depths. Severity of EAU was assessed on a scale of 0–4 as described previously [28].
Isolation of eye-infiltrating cells and preparation of retinal supernatant
Uveitic eyes were collected from 5 mice per group, and trimmed along the limbus for removal
of external tissue, as described previously [29]. Pooled retinal tissue was minced with scissors
in cRPMI containing complete protease inhibitor cocktail (Roche), and dissociated with vigor-
ous pipetting. After centrifugation, clarified supernatant (retinal extract) was used for ELISA.
Pellets were digested with 60 U/ml Liberase (Roche) for 1 h at 37°C, washed with cRPMI, and
passed through a 70 μm cell strainer to remove debris, and the cells were used for intracellular
staining as below.
Flow cytometry
Cells were stimulated with 50 ng/ml PMA and 500 ng/ml ionomycin (both Sigma) for 4 h in
the presence of GolgiStop (BD) before intracellular cytokine staining. Cells were first stained
for the surface markers CD4, neuropilin-1, CTLA-4, and/or CD103, and then fixed with Cyto-
fix Buffer (BD) for cytokine staining or Fixation/Permeabilization Buffer (eBioscience) for
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nuclear staining of Foxp3. Cells were stained with appropriately diluted fluorophore-labeled
antibodies against intracellular targets (Foxp3, IL-4, IFNγ, IL-17A) in buffer containing 0.5%
saponin (Sigma). Flow cytometry was performed on a FACS Calibur (BD), and data were ana-
lyzed with FlowJo software (Tree Star). Gates were set based on appropriate isotype controls.
Where indicated, Fold Change represents percentage or number of marker positive cells in
gated population as compared to control. On overlayed histograms, % of Max represents the
total number of cells at a given fluorescence intensity compared to the maximum number of
cells at any intensity for a given sample.
Cytokine ELISA
Retinal extracts were assayed directly. Supernatants from dLN cell cultures were collected 48 h
after activation with 30 μg/ml IRBP1-20 and secreted cytokines in the supernatants were mea-
sured by ELISA using kits with purified capture and biotinylated detection antibodies against
IFNγ, IL-4, IL-17A, and IL-10 (eBioscience). Where indicated, fold change represents concen-
tration of cytokine as compared to vehicle treatment.
Statistical analysis
Statistical analysis was performed using two-way unpaired Student’s t test as indicated. Analy-
sis of uveitis scores and histopathology was performed using the Mann-Whitney U nonpara-
metric test. P-values were considered statistically significant at p< 0.05 (), p< 0.01 (),
p< 0.001 (), p< 0.0001 ().
Results
Galectin-8 attenuates retinal pathology in experimental autoimmune
uveitis
EAU is an ocular autoimmune disease driven by TH1 and TH17 cells and ameliorated by Treg
cells [6],[29]. To determine whether Gal-8 has anti-inflammatory activity in vivo, EAU was
induced in two groups of mice by subcutaneous immunization with IRBP1-20 emulsified in
CFA, along with simultaneous i.p. injections of pertussis toxin [25],[26]. One group of mice
received 7 doses of Gal-8 (50 μg in 100 μl) on the indicated days (Fig 1A). The control group of
mice received i.p. injections of vehicle alone. No notable side effects or behavioral changes were
detected after Gal-8 treatment. Eyes were imaged on the day of immunization and 24 days
later, at the termination of the experiment (Fig 1A). Representative fundus (inner lining of the
eye) images of the central retina of mice treated with either vehicle or recombinant Gal-8 on
day 24 p.i. are shown in Fig 1B. The images were scored for vascular changes, immune cell infil-
tration, optic disc inflammation, and structural damage, and the four scores were averaged to
give an overall clinical score. Inflammatory lesions were more prevalent in retinas from vehi-
cle-treated compared to Gal-8-treated mice (Fig 1B, white arrowheads). Vehicle-treated mice
also exhibited large, discolored regions of atrophy in the central retina (Fig 1B, green outline).
In contrast, little atrophy was seen in the retinas of Gal-8-treated mice. Also, Gal-8 treatment
substantially reduced optic disc inflammation detected in the vehicle-treated mice (Fig 1B, blue
arrowhead). Overall, compared to vehicle-treated mice, retinas of Gal-8-treated mice had sig-
nificantly reduced vascular swelling, cuffing and immune cell infiltration (Fig 1C and 1D),
reduced inflammation of the optic disc and structural changes, and reduced overall clinical
score (Fig 1E). Thus, treatment with Gal-8 reduces EAU pathology.
To determine whether treatment with Gal-8 affected damage to the neural retina during
EAU, 24 days p.i., retinal lesions were identified by fundus imaging, and then imaged by OCT,
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a commonly used clinical technique that allows cross sectional imaging of live tissue. Vehicle-
treated mice contained infiltration of cells into the vitreous (V, orange arrowhead), as well as
hyper-reflective material in the outer nuclear layer (ONL, Fig 2A, yellow arrowhead), possibly
indicative of active inflammation, as expected. Additionally, these mice had inflammatory
debris in the inner nuclear layer (INL, Fig 2A, red arrowhead) and degradation of the external
Fig 1. Galectin-8 ameliorates EAU pathology. (A) B6 mice were immunized with IRBP peptide (1–20) to induce uveitis. Groups of at least 5 mice each
were injected with vehicle or Gal-8 and imaged as indicated. (B) Representative fundus images of vehicle- and Gal-8-treated mice at day 0 and 24. Blue
arrowhead: optic disc inflammation; white arrowhead: immune cell infiltrates; red arrowhead: engorged vasculature; green dotted line: retinal atrophy. Retinal
vascular changes (C), lymphocyte infiltration to the retina (D), and overall uveitis clinical score (E) were determined for the most severe eye of each mouse
and averaged across three independent experiments with at least five vehicle- and five Gal-8-treated mice each. Error bars are SEM from three independent
experiments with a total of 18 vehicle- and 20 Gal-8-treated mice. P values were determined by Mann-Whitney U test. *, p < 0.05.
doi:10.1371/journal.pone.0130772.g001
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Fig 2. Galectin-8 treatment reduces damage to the neural retina. B6mice were immunized with IRBP peptide and injected with vehicle or Gal-8 as shown
in Fig 1. (A) Representative OCT images of retinal lesions at day 24 p.i. Composite images are average of ten adjacent images. Red arrowhead:
inflammatory debris; green arrowhead: degradation of the ELM and IS/OS; yellow arrowhead: disruption of the middle retina by hyper-reflective material;
orange arrowhead: vitreous infiltrate. Vertical and horizontal scale bars, 50 μm. Images are representative from three independent experiments with a total of
18 vehicle- and 20 Gal-8-treated mice (B) Representative histopathology of damage to the retina in vehicle- and Gal-8-treated mice at day 24 p.i. White
arrowhead: disruption of the INL; blue arrowhead: retinal folding. Scale bar, 50 μm. Images are representative of two independent experiments with 5 vehicle-
and 5 Gal-8-treated eyes. V: vitreous; GC: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OPL: outer plexiform layer; ONL: outer
nuclear layer; ELM: external limiting membrane; IS/OS: Inner segment/ outer segment junction; RPE: retinal pigment epithelium. (C) Histopathology scores
of vehicle- and Gal-8-treated eyes. At least 10 slides from different depths were scored and averaged to give a value for each eye. Error bars are
mean ± SEM from two independent experiments with 5 vehicle- and 5 Gal-8-treated eyes. P values were determined by Mann-Whitney U test. *, p < 0.05.
doi:10.1371/journal.pone.0130772.g002
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limiting membrane (ELM) and inner segment/outer segment (IS/OS) junction (Fig 2A, green
arrowhead), suggesting photoreceptor cell damage. Lesions in Gal-8-treated mice primarily
had reduced vitreous infiltrates, and little to no disturbance of the photoreceptors (Fig 2A).
These results were confirmed by histopathology of eyes at 24 days p.i. (Fig 2B). In vehicle-
treated mice, we observed ONL folding, granulomatous infiltration, and regions of discontinu-
ity of the INL (Fig 2B). In contrast, Gal-8-treated mice had significantly reduced pathology
scores (Fig 2B), and primarily had sparse infiltrating retinal cells without characteristics of
severe inflammation or damage (Fig 2C), in agreement with the fundoscopy and OCT analysis.
Gal-8 treatment in vivo enhances the Treg cell response in draining
lymph nodes
During ocular inflammation, T cells are primarily activated in the cervical and submandibular
dLNs. To determine whether Gal-8 ameliorates EAU pathology by influencing T cell differenti-
ation, dLN from vehicle- and Gal-8-treated mice collected on day 24 p.i. were examined for the
presence of T cell subsets by flow cytometry. Representative scatter plots gated on CD4+ cells
are shown in Fig 3A. We found an increase in Treg cell frequency as well as number in the dLN
of Gal-8-treated mice compared to vehicle-treated controls (Fig 3A). Although there was an
increase in both the frequency and number of TH2 cells in the dLN of Gal-8-treated mice, this
difference was not statistically significant. There was no difference in TH1 cells between the two
groups (Fig 3A), but a 1.2-fold increase in total TH17 cells in the dLN of Gal-8-treated mice
compared to the vehicle-treated control mice (Fig 3A). We observed no difference in frequency
or number of CD4+ T cell populations in the spleen of Gal-8-treated mice as compared to vehi-
cle-treated mice (Fig 3B). In addition, when dLN cells were restimulated ex vivo with IRBP1-20
for 2 days, and cytokines in the supernatant were measured by ELISA, cells from the dLN of
Gal-8-treated mice secreted 4.4- and 3.5-fold more IL-10 and IL-4, respectively, than the cells
from vehicle-treated mice, while IFNγ and IL-17A secretion were unaffected (Fig 3C).
To assess the functional potential of Gal-8-induced Treg cells, dLN cells from vehicle- or
Gal-8-treated mice were stained for CTLA-4 and IL-10, as well as for the tissue-homing integ-
rin CD103, by flow cytometry. Scatter plots gated on CD4+Foxp3+ cells are shown in Fig 4A.
The frequency (Fig 4B) and total number (Fig 4C) of CTLA-4+ and IL-10+ Treg cells was
increased in the dLN of Gal-8-treated mice compared with control animals. Although there
was no difference in the frequency (Fig 4B), there was a significantly higher number of CD103+
Treg cells in the dLN of Gal-8-treated mice (Fig 4C). Because CD103 is important for retention
of Treg cells in the inflamed tissue [30], we next tested whether Treg cells would accumulate in
the retina of Gal-8-treated mice, where CTLA-4 and IL-10 could inhibit activation and func-
tion of pathogenic TH1 and TH17 cells.
Gal-8 treatment promotes a local anti-inflammatory response in the
retina
Retinal damage in EAU is mediated by cytokine production from TH1 and TH17 cells and can
be inhibited by the action of Treg cells [6],[29]. To determine the effect of Gal-8 treatment on
the local retinal immune environment, we analyzed T cell subsets in the retina of vehicle- and
Gal-8-treated mice by flow cytometry (Fig 5A). Compared to the vehicle-treated control mice,
there was a 25% increase in Treg cell frequency and a 50% increase in Treg number in the ret-
ina of Gal-8-treated mice (Fig 5A). The frequency of TH2 cells was 50% higher in Gal-8-treated
versus vehicle-treated retinas, which resulted in a 34% increase in total retinal TH2 cells (Fig
5A). There was no significant difference in the number or frequency of TH1 cells in the retinas
of Gal-8-treated mice, but the frequency of TH17 cells was reduced by 37% compared to
Galectin-8 Promotes Treg and Ameliorates Ocular Autoimmunity
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Fig 3. Galectin-8 promotes Treg cell differentiation in the dLN during EAU. dLN and spleen cells were collected from uveitic mice treated with Gal-8 or
vehicle 24 d p.i. Cells from the dLN (A) or spleen (B) were stained for Foxp3, IL-4, IFNγ, and IL-17A, and representative scatter plots gated on CD4+ are
shown, along with frequency and total number of each T cell subset. (C) Cytokine secretion from dLN cells stimulated ex vivowith IRBP1-20 for 48 h. FACS
and ELISA samples were measured in triplicate. Error bars are mean ± SEM from three independent experiments with 18 vehicle- and 20 Gal-8-treated mice.
P values were determined by Student’s t test. *, p < 0.05; ****, p < 0.0001.
doi:10.1371/journal.pone.0130772.g003
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vehicle-treated mice (Fig 5A). The ratio of Treg: TH1 cells was increased 1.6-fold and the ratio
of Treg: TH17 cells was increased 1.7-fold in the retinas of Gal-8-treated mice compared to
vehicle treatment (Fig 5B). The anti-inflammatory cytokine IL-10 was increased by 34% in
retinal extracts from the Gal-8-treated group compared to the vehicle-treated control group
(Fig 5C). In contrast, there was a dramatic decrease in soluble retinal IFNγ and IL-17A in Gal-
8-treated mice (Fig 5C), consistent with the reduced pathology of these mice.
Neuropilin-1 is specifically expressed by Treg cells that originate in the thymus, but is not
expressed on Treg cells induced in the periphery [31]. In the retina of vehicle-treated mice,
56% of Treg cells expressed neuropilin-1, whereas only 9% of retina-infiltrating Treg cells in
Fig 4. Galectin-8 promotes dLN Treg cell expression of suppressivemolecules CTLA-4 and IL-10, and tissue-homing integrin CD103.
Representative scatter plots (A), as well as frequency (B) and number (C) of CTLA-4, IL-10, and CD103 expressing Treg cells from the dLN of vehicle- and
Gal-8-treated mice with uveitis. FACS samples were measured in triplicate. Error bars are mean ± SEM from three independent experiments with a total of 18
vehicle- and 20 Gal-8-treated mice. P values were determined by Student’s t test. *, p < 0.05; **, p < 0.01.
doi:10.1371/journal.pone.0130772.g004
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Fig 5. Galectin-8 inhibits inflammation of the retina. Retina-infiltrating cells were collected from uveitic mice treated with Gal-8 or vehicle at 24 d p.i. (A)
Representative scatter plots of Foxp3, IL-4, IFNγ, and IL-17A staining are shown, and frequency and number of retinal Treg, TH2, TH1, and TH17 cells are
quantified. (B) Cell ratios for total numbers of Treg per TH1 cell and Treg per TH17 cell in the retina. (C) Cytokines in pooled retinal extracts were measured by
ELISA. (A-C) Retinas from five mice per group were pooled, and data are reported as fold change over control. Because of the limiting number of retinal
lymphocytes, only one pooled FACS replicate was measured per group per experiment. ELISA samples were measured in quadruplicate. Error bars
represent mean ± SEM of two independent experiments. P values were determined by Student’s t test. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****,
p < 0.0001.
doi:10.1371/journal.pone.0130772.g005
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Gal-8-treated mice expressed neuropilin-1. This suggests that 90% of Treg cells in the Gal-
8-treated retinas are of extra-thymic origin (Fig 6A). Consistent with our observations in the
dLN (Fig 4), a higher percentage and number of retinal Treg cells from Gal-8-treated mice
expressed CTLA-4, IL-10, and CD103 (Fig 6B–6D). Taken together, these data suggest that
Fig 6. Treg cells in Gal-8-treated retinas are highly anti-inflammatory, inducible Treg cells. Retina-infiltrating cells were collected from uveitic mice
treated with Gal-8 or vehicle at 24 d p.i. (A) Representative scatter plots show neuropilin-1 staining of Foxp3+ Treg cells. (B-D) Representative scatter plots
(B), as well as frequency (C) and number (D) of CTLA-4, IL-10, and CD103 positive retinal Treg cells. (B-D) Retinas from five mice per group were pooled,
and data are reported as fold change over control. Because of the limiting number of retinal lymphocytes, only one pooled FACS replicate was measured per
group per experiment. Error bars represent mean ± SEM of two independent experiments. P values were determined by Student’s t test. *, p < 0.05; **,
p < 0.01; ***, p < 0.001.
doi:10.1371/journal.pone.0130772.g006
Galectin-8 Promotes Treg and Ameliorates Ocular Autoimmunity
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Gal-8 treatment modulates the severity of EAU pathology by enhancing anti-inflammatory
Treg cell responses.
Discussion
Autoimmune uveitis is a potentially blinding disease associated with TH1 and TH17 cytokine
production and ameliorated by Treg cells. Despite rodent models of EAU that reproduce
aspects of the human disease, development of rational treatments for uveitis has been slow. To
the best of our knowledge, this is the first report demonstrating that Gal-8, a carbohydrate-
binding protein, ameliorates EAU pathology. Gal-8 treatment in the mouse model of EAU: (i)
resulted in increased frequency and number of CTLA-4+, IL-10+, and CD103+ Treg cells in the
dLN and retina, and (ii) downregulated the production of proinflammatory cytokines, IFNγ
and IL-17A, and upregulated the levels of the anti-inflammatory cytokine IL-10, in the retina.
Taken together, these results indicate that Gal-8 functions as an anti-inflammatory protein and
could serve as a valuable therapeutic intervention not only for uveitis, but also for a broad
range of autoimmune and chronic inflammatory conditions.
In the EAU model, Gal-8 also promoted development of TH2 cells, which has been associ-
ated with less severe EAU pathology. Strains of mice with an inherent TH2 bias are generally
resistant to induction of EAU [32]. Others have demonstrated that skewing the T cell response
away from TH1 and TH17 to TH2 and Treg significantly ameliorates EAU pathology [33],[34],
although the precise mechanism by which TH2 cells inhibit EAU is still poorly understood.
Additional studies are needed to directly ascertain the relative importance of the increased
TH2-type response evoked in the Gal-8 treated mice in the current study. The role of CD4
+
effector T cells, particularly TH1 and TH17 cells is well documented in the pathogenesis of
EAU. Because either TH1 or TH17 cells can drive immunopathology in EAU [29], an effective
therapy should ideally target both TH1 and TH17 cells. In this regard, our finding that treat-
ment with Gal-8 during the course of uveitis markedly decreases the soluble levels of both the
TH1 cytokine, IFNγ, as well as the TH17 cytokine, IL-17A, in the retina is of interest. Likewise,
our finding that Gal-8 treatment in the EAU model enhances soluble IL-10 in the retina is of
potential therapeutic value. IL-10 is thought to play a critical role in the inhibition of EAU
pathology. IL-10 mRNA expression was shown to increase during the natural resolution of rat
EAU [35]. Moreover, treatment with recombinant IL-10 inhibits EAU, whereas administration
of an anti-IL-10 Ab significantly exacerbates pathology [36]. We observed that Gal-8 treatment
i.p. affects T cell differentiation at sites of active inflammation, such as the dLN and retina, but
does not systemically alter the differentiation state of naïve T cells, as we observed no change in
CD4+ T cell subpopulation frequency in the spleen. This is consistent with the emerging role of
galectins in restoration of immune homeostasis [7],[18],[21].
The data in the present study do not exclude the possibility that Gal-8 may have additional
effects on other immune cell types to decrease EAU pathology, however the role of Gal-8 in the
function of most immune cells is still poorly understood. Lupus patients often have high titers
of anti-Gal-8 serum autoAbs [37], suggesting that Gal-8 plays an anti-inflammatory role in an
autoimmune disease with little T cell involvement. Gal-8 has been shown to promote neutro-
phil adhesion and superoxide production via the C-terminal CRD [38], as well as plasma cell
differentiation and antibody production [39]. Additionally, Gal-8 is expressed in the thymus
and can induce apoptosis of thymocytes, which has been postulated to play a role in tolerance
[40]. Although it is possible that Gal-8 may affect development of Treg cells in the thymus
(nTreg cells), our finding that the majority of Treg cells in Gal-8-treated retinas are peripher-
ally-induced iTreg cells suggests that Gal-8 either promotes the differentiation or recruitment
of iTreg cells.
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Others have demonstrated that Gal-1 and Gal-9 positively regulate Treg cell function [11],
[12],[21], whereas Gal-3 negatively regulates Treg cell expansion in the context of autoimmu-
nity [41]. In this respect, in a preliminary study, we have observed that Gal-8 promotes Ag-spe-
cific and polyclonal differentiation of Treg cells in vitro (Sampson and Panjwani, unpublished
observations). Although most members of the galectin family bind galactose-containing resi-
dues, variability in the CRD among galectins results in unique fine specificities for more com-
plex galactose-containing oligosaccharides [42]. As a result, each galectin may have profoundly
different ligand preference based on glycosylation patterns, with consequent specific down-
stream effects [19],[43],[44]. In this respect, the carbohydrate-binding affinity of the N-
terminal CRD of Gal-8 is unique among members of galectin family in that it has a high affinity
for 3’- sialylated glycoconjugates [45]. This unique carbohydrate specificity and structure could
make Gal-8 a selective drug target.
Finally, our finding that Gal-8 treatment ameliorates EAU pathology has broad implications
for developing novel therapeutic strategies not only for uveitis but also for a wide array of auto-
immune diseases including multiple sclerosis, ulcerative colitis, and atherosclerosis, which are
mediated by TH1 and TH17 cytokines and ameliorated by the action of Treg cells [41],[46],
[47]. The most common treatment for uveitis and other autoimmune disorders has not
changed in decades. Therapy is based on nonspecific immunosuppression, such as corticoste-
roids and TNFα blocking agents, despite the fact that these treatments are well known to be
associated with severe side effects and toxicity, leaving patients immunocompromised and sus-
ceptible to opportunistic infection or reactivation of latent tuberculosis [48]. Thus, there is a
clear unmet need for developing more specific treatments based on increased understanding of
basic disease mechanisms. It is our hope that Gal-8-based therapies could serve to ameliorate
the clinical outcome of human uveitis and other TH1- and TH17-mediated autoimmune
pathologies.
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